کد مقاله کد نشریه سال انتشار مقاله انگلیسی ترجمه فارسی نسخه تمام متن
5666950 1407839 2017 3 صفحه PDF ندارد دانلود رایگان
عنوان انگلیسی مقاله
Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis
کلمات کلیدی
Mycobacterium tuberculosis; MDR/XDR tuberculosis; Adverse events; Amikacin; Second-line injectable antituberculosis drugs; Nebulized aminoglycosides;
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis
چکیده انگلیسی

•The efficacy of aminoglycosides against multi-drug-resistant (MDR) bacilli is preserved.•Aminoglycosides cause frequent adverse events.•The average duration of amikacin IV treatment is usually less than recommended by World Health Organization.•The place of amikacin should be re-evaluated, including its route of administration.

Second-line injectable antituberculosis drugs (aminoglycosides and capreomycin) are the main drugs used in the management of resistant tuberculosis. Their preserved efficacy in the case of multi-drug-resistant bacillus is counterbalanced by frequent adverse events. Adverse events are linked to the drugs themselves and to the recommended 8-month period of parenteral administration. In numerous countries facing a high incidence of multi-drug-resistant tuberculosis, treatment is administered by intramuscular injection. This procedure is painful and restrictive, and therefore treatment adherence is limited. This study reports the follow-up of 11 patients diagnosed with multi-drug- and extensively-resistant tuberculosis and treated with parenteral amikacin, and discusses the role of amikacin in the treatment of resistant tuberculosis.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 50, Issue 2, August 2017, Pages 252-254
نویسندگان
, , , ,